Cargando…
Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer
BACKGROUND: Evidence for use of second-line immunosuppressants for immune-related adverse events (irAEs) is inadequate. Therefore, a multicenter analysis should assess the efficacy of second-line immunosuppressants for severe irAEs associated with different malignant diseases. METHODS: This descript...
Autores principales: | Ogusu, Shinsuke, Harutani, Yuhei, Tozuka, Takehiro, Saito, Ryota, Koyama, Junji, Sakamoto, Hiroaki, Sonoda, Tomoaki, Tsuchiya-Kawano, Yuko, Oba, Tomohiro, Kudo, Keita, Gyotoku, Hiroshi, Nakatomi, Katsumi, Ariyasu, Ryo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576678/ https://www.ncbi.nlm.nih.gov/pubmed/37638979 http://dx.doi.org/10.1007/s00262-023-03528-x |
Ejemplares similares
-
Clinical influence of switching companion diagnostic tests for EGFR‐TKs from Therascreen to Cobas v2
por: Uchibori, Ken, et al.
Publicado: (2021) -
Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib
por: Sakamoto, Hiroaki, et al.
Publicado: (2021) -
Feasibility of next‐generation sequencing test for patients with advanced NSCLC in clinical practice
por: Ariyasu, Ryo, et al.
Publicado: (2020) -
Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first‐line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021‐01)
por: Uematsu, Shinya, et al.
Publicado: (2022) -
Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with Genexus™ integrated sequencer
por: Low, Siew-Kee, et al.
Publicado: (2022)